Cambridge Isotope Laboratories, Inc. Announces (13)C Cascade Production Optimization at Ohio Plant

USA - English

• India - English

TEWKSBURY, Mass., Dec. 16, 2020 /PRNewswire/ -- Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (¹³C), recently began a significant capacity optimization of one of the production cascades at the ¹³C separation facility in Xenia, Ohio. This optimization, which began this past summer and is scheduled for completion in the summer of 2021, will increase the cascade's ¹³C production by 10%. This follows the most recent expansion completion earlier this year, which increased ¹³C production capacity by 25%.

"In response to increased demand for ¹³C and ¹³C urea, our engineering team has been working on initiatives designed to provide the additional capacity required to ensure meeting our long-term contractual obligations for our customer demand," states Cliff Caldwell, CEO.

"As we work to increase our operations and capabilities for our customers we sometimes need to think creatively for better solutions. This project is an example of using different problem-solving methods to achieve a better operating production cascade," says Mike Steiger, VP of Project Engineering and Execution.

CIL's isotope-separation facility houses the world's largest ¹³C and one of the world's largest 18O isotope-separation facilities. This facility also has the world's only commercial D2O enrichment columns. These factors allow CIL to continue to be the world's leading producer of stable isotopes and stable isotope-labeled compounds for analytical and research applications. Having process control of stable isotope starting materials ensures inventory of needed synthetic precursors and allows tight control over the product quality demanded by CIL.

About Cambridge Isotope Laboratories, Inc.

CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France.

For more information on CIL, visit isotope.com.

Related Images

cambridge-isotope-laboratories-inc.jpg
Cambridge Isotope Laboratories, Inc. Announces 13C Cascade Production Optimization at Ohio Plant

SOURCE Cambridge Isotope Laboratories, Inc.

Related Links

http://www.isotope.com